The landscape of cancer detection is evolving rapidly, driven by advancements in artificial intelligence and liquid biopsy technologies, according to BCC Research's latest report.
The global molecular diagnostics market, valued at $20.3 billion in 2024, is projected to grow significantly, reaching $42.6 billion by 2030. This growth, estimated at a compound annual growth rate (CAGR) of 13.1%, is fueled by technological innovations and increased investments in healthcare infrastructure. North America currently leads this market, benefiting from robust healthcare systems and favorable reimbursement policies that support early adoption of advanced screening technologies.
Liquid biopsies, in particular, are experiencing remarkable growth, with projections indicating an increase from $2.1 billion in 2024 to $6.3 billion by 2029, achieving a CAGR of 24.6%. This surge reflects a broader trend towards non-invasive cancer screening methods. Additionally, the tissue diagnostics market is set to expand at an 8.7% CAGR, driven by developments in companion diagnostics and personalized medicine.
As artificial intelligence continues to integrate into oncology diagnostics, it is enhancing both diagnosis and treatment planning. Established companies like Roche and Illumina dominate the market, but the increasing demand for advanced diagnostic technologies is reshaping competitive dynamics. The convergence of an aging population, rising cancer rates, and healthcare investments in emerging markets is creating a pressing need for innovative diagnostic solutions, particularly those that enable early detection and intervention.